Rhythm Pharmaceuticals Launches IMCIVREE in Japan After NHI Listing
IMCIVREE is approved in Japan for acquired hypothalamic obesity and is included on the NHI drug price list. It is the first approved therapy in Japan for the condition.
IMCIVREE is approved in Japan for acquired hypothalamic obesity and is included on the NHI drug price list. It is the first approved therapy in Japan for the condition.